Loading
Life sciences · Journal article
European Journal of Medicinal Chemistry · September 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
In our continuing campaign to discover novel inhibitors of the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) protein 3 (NLRP3), an emerging drug target that tightly regulates the innate immune responses, a 1H-1,2,3-triazole-4-carboxamide scaffold was designed and optimized. Iterative optimization led to the identification of a lead inhibitor, 22, with an IC50 of 70 nM to suppress the release of interleukin (IL)-1β upon NLRP3 activation. Further in vivo studies supported its selective suppression of the NLRP3 inflammasome. Pharmacokinetic studies of 22 and PET imaging studies employing a F-18 tracer of 22 demonstrated 22 as a brain penetrant with reversible binding kinetics within the CNS. Importantly, treatment of AD patient-derived hiPSC glia cells including microglia and astrocytes and neuropathic pain mice with 22 led to suppression of NLRP3 expression and decreased pain and pain-like behavior, supporting the translational promise of this compound and analogs from this chemotype.